The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas
Open accessAbstract
Purpose: To evaluate the toxicity profile, pharmacologic, and biological properties of 3-pyridylmethyl N-{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate (MS-275), a histone deacetylase inhibitor, when administered orally on three different dosing schedules. Experimental Design: Patients with advanced solid malignancies and lymphomas were treated on three dose schedules: once every other week, twice weekly for 3 weeks every 28 days, and once weekly for 3 weeks every 28 days. First-cycle plasma pharmacokinetics and peripheral blood mononuclear cell histone acetylation were determined. Results: Twenty-seven patients received ≥149 courses of treatment. Hypophosphatemia and asthenia were dose limiting on the weekly and twice-weekly dosing schedules; there was no dose-limiting toxicity on the every other week schedule. Pharmacokinetic variables revealed dose-dependent and dose-proportional increases. Two of 27 patients showed partial remissions, including one patient with metastatic melanoma who had a partial response and has remained on study for >5 years. Six patients showed prolonged disease stabilization. Levels of histone H3 and H4 acetylation in peripheral blood mononuclear cells increased qualitatively but with a high degree of interpatient variation. Conclusions: MS-275 is well tolerated at doses up to 6 mg/m2 every other week or 4 mg/m2 weekly for 3 weeks followed by 1 week of rest and results in biologically relevant plasma concentrations and antitumor activity. Twice-weekly dosing was not tolerable due to asthenia, and further evaluation of this schedule was halted. The recommended dose for further disease-focused studies is 4 mg/m2 given weekly for 3 weeks every 28 days or 2 to 6 mg/m2 given once every other week.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most common toxicities observed included fatigue and hematologic, gastrointestinal, and metabolic AEs, similar to previous studies incorporating entinostat.11,14,15”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Zhang, Y., & Reinberg, D. (2001) · Genes & Development · doi:10.1101/gad.927301 · Cited by 1,639
Histone and chromatin cross-talk
Fischle, W., Wang, Y., & Allis, C. D. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00013-9 · Cited by 1,239
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 696
Kelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 620
Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
Warrell, R. P., He, L.-Z., Richon, V., Calleja, E., & Pandolfi, P. P. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1621 · Cited by 502
(2003) · PubMed · Cited by 465
Ryan, Q. C., Headlee, D. J., Acharya, M. R., Sparreboom, A., Trepel, J. B., Ye, Z., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.188 · Cited by 415
Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-05-1693 · Cited by 401
Jaboin, J. J., Wild, J., Hamidi, H., Khanna, C., Kim, C. J., Robey, R. W., Bates, S. E., & Thiele, C. J. (2002) · PubMed · Cited by 224
Lucas, D. M., Davis, M. E., Parthun, M. R., Mone, A. P., Kitada, S., Cunningham, K. D., Flax, E. L., Wickham, J., Reed, J. C., Byrd, J. C., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403388 · Cited by 135
Lee, B. I., Park, S. H., Kim, J. W., Sausville, E. A., Kim, H. T., Nakanishi, O., Trepel, J. B., & Kim, S. J. (2001) · PubMed · Cited by 120
Histone deacetylase inhibitors and cancer: from cell biology to the clinic
Hess‐Stumpp, H. (2005) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2004.12.010 · Cited by 117
The functions of the cdk-cyclin kinase inhibitor p21WAF1.
Boulaire, J., Fotedar, A., & Fotedar, R. (2000) · PubMed · Cited by 110
Park, S. H., Lee, S. R., Kim, B. C., Cho, E. A., Patel, S. P., Kang, H., Sausville, E. A., Nakanishi, O., Trepel, J. B., Lee, B. I., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106451200 · Cited by 80
Kano, Y., Akutsu, M., Tsunoda, S., Izumi, T., Kobayashi, H., Mano, H., & Furukawa, Y. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9000-0 · Cited by 48
Kawano, T., Horiguchi‐Yamada, J., Iwase, S., Akiyama, M., Furukawa, Y., Kano, Y., & Yamada, H. (2004) · PubMed · Cited by 25
Hwang, K., Acharya, M. R., Sausville, E. A., Zhai, S., Woo, E. W., Venitz, J., Figg, W. D., & Sparreboom, A. (2004) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.01.023 · Cited by 15
Research works printed but not linked: 2
- Wei Y, Qian, DZ, Ren M, et al. In vivo real-time imaging of transcriptional activation of the RARβ gene promoter by the histone deacetylase inhibitor MS-275 in a prostate cancer model. In: Proceedings of the AACR; 2004; Orlando, FL.
- Qian D, Wang XF, Ren MQ, et al. The histone deacetylase inhibitor MS-275 inhibits prostate tumor growth. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2003, Boston, MA.
Cited by
Sorted by citations
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 893
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T. L., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 698
(2011) · PubMed Central · Cited by 560
Metadata
- Authors
- Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., & Eckhardt, S. G.
- Affiliations
- University of Colorado Cancer Center (US)
- Vanderbilt-Ingram Cancer Center (US)
- 1University of Colorado Cancer Center, Aurora, Colorado;
- 3Bayer Healthcare, Seattle, Washington; and
- Bayer (Germany) (DE)
- Venue
- Clinical Cancer Research
- Published
- 2008-07-15
- Volume
- 14
- Issue
- 14
- Pages
- 4517-4525
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC2813676
- OpenAlex
- W2170925020
- Cited by
- 171
- References
- 21
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 9 · 2023: 5 · 2022: 3 · 2021: 11 · 2020: 7 · 2019: 8 · 2018: 6 · 2017: 9 · 2016: 9 · 2015: 8 · 2014: 10 · 2013: 15 · 2012: 13
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (NIH K12)
- Cancer Center, University of Colorado
- National Cancer Institute (CA-86913, K24CA106349, K12CA086913)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- entinostat, histone deacetylase inhibitors, oral administration, dosing regimen, pharmacokinetics, refractory solid tumors, lymphoma, hypophosphatemia, asthenia, histone H3 and H4 acetylation, peripheral blood mononuclear cells, metastatic melanoma, anticancer activity, toxicity
- MeSH terms
- Administration, Oral, Adult, Aged, Antineoplastic Agents, Benzamides, Enzyme Inhibitors, Female, Humans, Lymphoma, Male, Middle Aged, Neoplasms, Pyridines, Area Under Curve, Maximum Tolerated Dose, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
